GLP-1 agonism reversed aging signatures across organs in mice

Low-dose GLP-1 receptor agonism reversed multiple molecular signatures of aging across tissues, and it did so with minimal effect on body weight — effectively ruling out the weight-loss mechanism that dominates most coverage of these drugs. Mice treated later in life showed even stronger molecular rejuvenation than those treated earlier, an unusual timing pattern that inverts the conventional expectation that early intervention always wins. Some benefits depended specifically on GLP-1 signaling in the hypothalamus — the brain region that acts as the body's master regulator of metabolism, stress response, and aging rate — suggesting the drug's anti-aging effects run through the brain as much as through the gut.